SIGNIFICANCE OF INTRATUMORAL HER2 HETEROGENEITY IN BREAST CANCER AND USES THEREFOR

Disclosed herein are methods for predicting the response to a HER2-directed therapy and for scoring a breast cancer tumor sample. In some embodiments, the methods include contacting the sample with an antibody that specifically binds HER2 protein and detecting presence and/or amount of HER2 protein...

Full description

Saved in:
Bibliographic Details
Main Authors PADILLA, Mary T, DENNIS, Eslie, RANGER-MOORE, James, KUROZUMI, Sasagu, KUROSUMI, Masafumi, NITTA, Hiro
Format Patent
LanguageEnglish
French
German
Published 12.04.2017
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are methods for predicting the response to a HER2-directed therapy and for scoring a breast cancer tumor sample. In some embodiments, the methods include contacting the sample with an antibody that specifically binds HER2 protein and detecting presence and/or amount of HER2 protein and contacting the sample with a nucleic acid probe that specifically binds to HER2 genomic DNA and detecting presence and/or amount of HER2 genomic DNA (such as HER2 gene copy number). In some embodiments, the methods further include detection of a centromere nucleic acid (such as chromosome 17 centromere DNA) and contacting the sample with an antibody that specifically binds ER protein and detecting presence and/or amount of ER protein in the same sample.
Bibliography:Application Number: EP20150726957